Home NDC 58151-246 Lyrica CR
Product NDC 58151-246
11-digit product format 581510246
Labeler code 58151
Product ID 58151-246_67715d17-5ade-44ba-a5db-ba20d30d6da1
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name PREGABALIN
Dosage form TABLET, FILM COATED, EXTENDED RELEASE
Route ORAL
Labeler Viatris Specialty LLC
Application NDA209501
Marketing category NDA
Marketing start 2024-11-26
Substance PREGABALIN
Active strength 165 mg/1
DEA schedule CV
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 3 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N209501-001 LYRICA CR PREGABALIN 82.5MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2017-10-11 N209501-002 LYRICA CR PREGABALIN 165MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2017-10-11 N209501-003 LYRICA CR PREGABALIN 330MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2017-10-11
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 3 matching rows.
Orange Book patents# Current patent rows page 1 of 1 · 24 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N209501-001 10022447 2026-11-02 U-2136 2018-08-16 N209501-001 10022447 2026-11-02 U-2137 2018-08-16 N209501-001 8945620 2026-11-02 U-2136 Drug product 2017-11-09 N209501-001 8945620 2026-11-02 U-2137 Drug product 2017-11-09 N209501-001 9144559 2026-11-02 Drug product 2017-11-09 N209501-001 10022447*PED 2027-05-02 Pediatric extension N209501-001 8945620*PED 2027-05-02 Pediatric extension N209501-001 9144559*PED 2027-05-02 Pediatric extension N209501-002 10022447 2026-11-02 U-2136 2018-08-16 N209501-002 10022447 2026-11-02 U-2137 2018-08-16 N209501-002 8945620 2026-11-02 U-2136 Drug product 2017-11-09 N209501-002 8945620 2026-11-02 U-2137 Drug product 2017-11-09 N209501-002 9144559 2026-11-02 Drug product 2017-11-09 N209501-002 10022447*PED 2027-05-02 Pediatric extension N209501-002 8945620*PED 2027-05-02 Pediatric extension N209501-002 9144559*PED 2027-05-02 Pediatric extension N209501-003 10022447 2026-11-02 U-2136 2018-08-16 N209501-003 10022447 2026-11-02 U-2137 2018-08-16 N209501-003 8945620 2026-11-02 U-2136 Drug product 2017-11-09 N209501-003 8945620 2026-11-02 U-2137 Drug product 2017-11-09 N209501-003 9144559 2026-11-02 Drug product 2017-11-09 N209501-003 10022447*PED 2027-05-02 Pediatric extension N209501-003 8945620*PED 2027-05-02 Pediatric extension N209501-003 9144559*PED 2027-05-02 Pediatric extension
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 4 of 4 · 132 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-10-28 04:53 UTC 2022-10 N209501-001 LYRICA CR 82.5MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2017-10-11 f41ea6bd6efb…2022-10-28 04:53 UTC 2022-10 N209501-002 LYRICA CR 165MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2017-10-11 f41ea6bd6efb…2022-10-28 04:53 UTC 2022-10 N209501-003 LYRICA CR 330MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2017-10-11 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N209501-001 LYRICA CR 82.5MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2017-10-11 e64feba35796…2022-09-29 23:25 UTC 2022-09 N209501-002 LYRICA CR 165MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2017-10-11 e64feba35796…2022-09-29 23:25 UTC 2022-09 N209501-003 LYRICA CR 330MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2017-10-11 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N209501-001 LYRICA CR 82.5MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2017-10-11 cb3db0bc1861…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N209501-002 LYRICA CR 165MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2017-10-11 cb3db0bc1861…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N209501-003 LYRICA CR 330MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2017-10-11 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N209501-001 LYRICA CR 82.5MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2017-10-11 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N209501-002 LYRICA CR 165MG TABLET, EXTENDED RELEASE / ORAL AB RLD 2017-10-11 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N209501-003 LYRICA CR 330MG TABLET, EXTENDED RELEASE / ORAL AB RLD, RS 2017-10-11 a50c72e98297…
Observed Orange Book normalized TE history# Normalized TE history page 1 of 3 · 108 observed states.
Observed Orange Book patent history# Patent history page 1 of 27 · 1,080 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-10-15 13:18:30 2026-09 N209501-001 10022447 2026-11-02 U-2137 2018-08-16 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-001 10022447 2026-11-02 U-2136 2018-08-16 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-001 8945620 2026-11-02 U-2136 Drug product 2017-11-09 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-001 8945620 2026-11-02 U-2137 Drug product 2017-11-09 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-001 9144559 2026-11-02 Drug product 2017-11-09 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-001 10022447*PED 2027-05-02 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-001 8945620*PED 2027-05-02 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-001 9144559*PED 2027-05-02 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-002 10022447 2026-11-02 U-2137 2018-08-16 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-002 10022447 2026-11-02 U-2136 2018-08-16 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-002 8945620 2026-11-02 U-2137 Drug product 2017-11-09 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-002 8945620 2026-11-02 U-2136 Drug product 2017-11-09 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-002 9144559 2026-11-02 Drug product 2017-11-09 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-002 10022447*PED 2027-05-02 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-002 8945620*PED 2027-05-02 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-002 9144559*PED 2027-05-02 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-003 10022447 2026-11-02 U-2137 2018-08-16 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-003 10022447 2026-11-02 U-2136 2018-08-16 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-003 8945620 2026-11-02 U-2137 Drug product 2017-11-09 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-003 8945620 2026-11-02 U-2136 Drug product 2017-11-09 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-003 9144559 2026-11-02 Drug product 2017-11-09 c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-003 10022447*PED 2027-05-02 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-003 8945620*PED 2027-05-02 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N209501-003 9144559*PED 2027-05-02 Pediatric extension c2088c7a36db…2026-09-14 22:38:34 2026-08 N209501-001 10022447 2026-11-02 U-2137 2018-08-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-001 10022447 2026-11-02 U-2136 2018-08-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-001 8945620 2026-11-02 U-2136 Drug product 2017-11-09 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-001 8945620 2026-11-02 U-2137 Drug product 2017-11-09 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-001 9144559 2026-11-02 Drug product 2017-11-09 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-001 10022447*PED 2027-05-02 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-001 8945620*PED 2027-05-02 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-001 9144559*PED 2027-05-02 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-002 10022447 2026-11-02 U-2137 2018-08-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-002 10022447 2026-11-02 U-2136 2018-08-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-002 8945620 2026-11-02 U-2137 Drug product 2017-11-09 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-002 8945620 2026-11-02 U-2136 Drug product 2017-11-09 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-002 9144559 2026-11-02 Drug product 2017-11-09 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-002 10022447*PED 2027-05-02 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-002 8945620*PED 2027-05-02 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N209501-002 9144559*PED 2027-05-02 Pediatric extension 84e616aacf4f…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 45 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base Lyrica CR
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength PREGABALIN 165 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 55JG375S6M Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 6 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 1988974 Internal RxNorm lookup 1988977 Internal RxNorm lookup 1988980 Internal RxNorm lookup 1994389 Internal RxNorm lookup 1994392 Internal RxNorm lookup 1994395 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 58151-246-93 Lyrica CR 30 in 1 BOTTLE TABLET, FILM COATED, EXTENDED RE 30 7
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 58151-246 LYRICA CR (PREGABALIN) TABLET, FILM COATED, EXTENDED RELEASE [VIATRIS SPECIALTY LLC] 5 Current NDC, 1 package rows 20250508_f280bbd8-2af2-444a-bd96-e409337ca6dd.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Marketing start Sample Exclude flag Status 58151-246-93 58151024693 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (58151-246-93) 2024-11-26 No No Current